News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Integrated Biosystems And Stedim Incorporated Report New Patents

10/19/2005 5:11:16 PM

NAPA, Calif., May 11 /PRNewswire/ -- Integrated Biosystems, Inc. (IBI), the world's leading supplier of controlled freeze-thaw technology to the biopharmaceutical industry and STEDIM, the world's leading designer and manufacturer of single-use, sterile plastic bag systems today announced that two new patents have been issued relating to the new Celsius product line. Celsius, which is currently being launched in the US and Europe, by IBI, offers IBI's proprietary controlled freeze-thaw technology in disposable containers.

U.S. Patent No. 6,684,646 and U.S. Patent No. 6,698,213 both are granted for "Systems and methods for freezing, storing and thawing biopharmaceutical material" and cover a system for the controlled freezing, storing and thawing of a biopharmaceutical material including a protected flexible container. These are the first two patents issued jointly to the two companies since they formed a strategic development and commercialization partnership.

IBI now has eleven issued patents with several patent applications pending. These are the first patents issued with Integrated Biosystems and STEDIM as co-inventors. The strategic partnership was formed two years ago to develop and commercialize IBI's patented freeze-thaw technology incorporating STEDIM bag technology for use in the manufacturing of biopharmaceuticals.

"The issuance of these patents further strengthens our position as the market leader in controlled freeze-thaw technology," commented IBI CEO, John H. Brown. "I am very pleased that the technical merits of Celsius are recognized at a time when market demand for the new product is increasing rapidly."

"Celsius is the first milestone materializing the long term success IBI and STEDIM expect from their strategic partnership," commented Thierry Favreau, STEDIM's CEO. "Covered by a strong intellectual property and already adopted by 3 major bio-pharmaceutical companies, Celsius is an enabling technology that will help our customers to decouple their bio-processing operations and better manage their supply chain."

By extending the technology for use with disposable, flexible containers -- which IBI will market under the brand name Celsius-Pak -- the company now has access to a larger market. Many biopharmaceutical manufacturers have seen the advantages of using disposable products, such as the elimination of expensive cleaning procedures and are keen to incorporate them into their manufacturing processes. The new Celsius product line has been well received by the market. Although the full launch of Celsius started only at the beginning of this year, already orders have been received from three major biopharmaceutical companies. The product is now being shipped to customers and the company is gearing up production to accommodate the current and expected future demand.

About Integrated Biosystems, Inc.

Integrated Biosystems, Inc. (IBI) is the world's leading supplier of patented technology and equipment for the controlled freezing, thawing and frozen storage of biopharmaceutical intermediates and final bulk drug substances. IBI's product portfolio includes freeze-thaw systems and related handling equipment for R&D, Pilot and Full-Scale Manufacturing. The technology has been used for over 10 years at leading Biotech and Biopharma contract manufacturers and is currently an integral part of the manufacture of a variety of leading biopharmaceuticals.

IBI is a private company headquartered in Napa, CA with European facilities in Fribourg (Switzerland) and Aubagne (France) and Engineering and Manufacturing operations in Springfield, MO.

For further information contact Richard Eagling, Vice-President Marketing and General Manager, Europe ( or go to


STEDIM is the world's leading designer and manufacturer of single-use, sterile plastic bag systems, replacing traditional glassware and stainless steel vessels for the manufacture and the packaging of medical and biopharmaceutical products. Developed since 1990, STEDIM's biotechnology and drug delivery operations provide all types of bag systems, answering the needs of biopharmaceutical laboratories and manufacturers for the development, manufacturing process, packaging and administration of therapeutic drugs, from Drug Discovery to Drug Delivery.

STEDIM is headquartered in Aubagne, with major companies, in Concord, CA, and more than 15 countries. STEDIM is listed on the Second Marche of the Euronext Paris S.A. (France Euroclear code : 5326). Further information is available at

Integrated Biosystems, Inc.

CONTACT: Richard Eagling, Vice-President Marketing and General Manager,Europe, of Integrated Biosystems, Inc., +1-707-226-9300, ext. 237,

Read at

comments powered by Disqus